Literature DB >> 7871094

Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies.

W Maier1, O Benkert.   

Abstract

Systematic variation of treatment (alternating active drug and placebo in four treatment periods) in individual patients is proposed to collect preliminary evidence for a therapeutic effect of sulpiride in chronic depression; the ARIMA model is applied to evaluate the intervention effects of the tentatively effective treatment in single subjects. Ten single cases of chronic depression with a diagnosis of major depression or dysthymia were selected and seven of these provided evidence for beneficial effects of sulpiride with regard to treating the symptoms of depression and anxiety. However, the drug effects were intraindividually not always replicable. The results obtained with these single cases positively support the recommendation to perform regular randomized placebo-controlled trials with sulpiride in chronic depression. Simultaneously, these single case investigations reveal a lack of temporal stability of treatment response and inconsistencies of response with regard to different treatment targets in individual patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7871094     DOI: 10.1007/bf02245573

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

1.  The necessity of placebo application in psychotropic drug trials.

Authors:  O Benkert; W Maier
Journal:  Pharmacopsychiatry       Date:  1990-09       Impact factor: 5.788

2.  The n-of-1 randomized controlled trial: clinical usefulness. Our three-year experience.

Authors:  G H Guyatt; J L Keller; R Jaeschke; D Rosenbloom; J D Adachi; M T Newhouse
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

3.  Comments on the paper by Möller et al. (1989): problems in single-case evaluation.

Authors:  J Krauth
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1990

4.  Repeated measures, interventions, and time series analysis.

Authors:  R H Jones
Journal:  Psychoneuroendocrinology       Date:  1985       Impact factor: 4.905

5.  N of 1 randomized trials for investigating new drugs.

Authors:  G H Guyatt; A Heyting; R Jaeschke; J Keller; J D Adachi; R S Roberts
Journal:  Control Clin Trials       Date:  1990-04

6.  Treatment for therapy-resistant depression.

Authors:  P Kielholz
Journal:  Psychopathology       Date:  1986       Impact factor: 1.944

7.  Imipramine treatment for chronic depression.

Authors:  J H Kocsis; A J Frances; C Voss; J J Mann; B J Mason; J Sweeney
Journal:  Arch Gen Psychiatry       Date:  1988-03

8.  Effect of sulpiride in endogenous depression.

Authors:  O Benkert; F Holsboer
Journal:  Acta Psychiatr Scand Suppl       Date:  1984

Review 9.  Acute therapy of depression.

Authors:  P Bech
Journal:  J Clin Psychiatry       Date:  1993-08       Impact factor: 4.384

10.  Determining optimal therapy--randomized trials in individual patients.

Authors:  G Guyatt; D Sackett; D W Taylor; J Chong; R Roberts; S Pugsley
Journal:  N Engl J Med       Date:  1986-04-03       Impact factor: 91.245

View more
  3 in total

1.  Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.

Authors:  Hideki Taoka; Takashi Hamamura; Shiro Endo; Shinji Miyata; Kishio Toma; Takeshi Ishihara; Shigetoshi Kuroda
Journal:  Psychopharmacology (Berl)       Date:  2008-09-06       Impact factor: 4.530

Review 2.  Personalized (N-of-1) Trials for Depression: A Systematic Review.

Authors:  Ian M Kronish; Meghan Hampsey; Louise Falzon; Beatrice Konrad; Karina W Davidson
Journal:  J Clin Psychopharmacol       Date:  2018-06       Impact factor: 3.153

3.  Precisely Fabricated Sulpiride-Loaded Nanolipospheres with Ameliorated Oral Bioavailability and Antidepressant Activity.

Authors:  Salma M Mohyeldin; Wael M Samy; Doaa Ragab; Doaa A Abdelmonsif; Rania G Aly; Nazik A Elgindy
Journal:  Int J Nanomedicine       Date:  2021-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.